Your browser doesn't support javascript.
loading
Cancer Risk in Patients with Gaucher Disease Using Real-World Data.
Revel-Vilk, Shoshana; Zimran, Ari; Istaiti, Majdolen; Azani, Liat; Shalev, Varda; Chodick, Gabriel; Manor, Orly; Paltiel, Ora.
Affiliation
  • Revel-Vilk S; Gaucher Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
  • Zimran A; Faculty of Medicine, The Hebrew University of Jerusalem, Ein Kerem, Jerusalem 9112102, Israel.
  • Istaiti M; Braun School of Public Health and Community Medicine, Hebrew University, Jerusalem 9112102, Israel.
  • Azani L; Gaucher Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
  • Shalev V; Faculty of Medicine, The Hebrew University of Jerusalem, Ein Kerem, Jerusalem 9112102, Israel.
  • Chodick G; Gaucher Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
  • Manor O; MaccabiTech, Maccabi Healthcare Services, Tel Aviv 6772168, Israel.
  • Paltiel O; School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
J Clin Med ; 12(24)2023 Dec 15.
Article in En | MEDLINE | ID: mdl-38137776
ABSTRACT
The association between GD and cancer has been uncertain due to ascertainment bias in previously published studies. We analyzed cancer incidence using the Maccabi Healthcare Service (MHS) electronic health records among 264 patients with GD compared to 3440 matched controls. We ascertained cancers diagnosed before and after the index date (i.e., the first documentation of GD in cases and the corresponding date for controls). Before the index date, cancers were diagnosed in 18 individuals, with 11 (4.2%) in the GD group and 7 (0.2%) in the control group. After the index date, cancers were diagnosed in 57 individuals, with 20 (7.9%) in the GD group and 37 (1.1%) in the control group, with a median follow-up of almost 13 years in both groups. The most common cancers diagnosed in GD were non-melanoma skin cancer (NMSC) and hematological malignancies, with a clustering of diagnoses around the time of GD diagnosis. The incidence of cancers (excluding MNSC) was 4.1 (95% CI 2.2-7.1) and 0.7 (95% CI 0.4-0.9) per 1000 patient-years in the GD and control groups, respectively, with an incidence rate ratio of 6.37 (95% CI 3-12.7). Patients with GD underwent more cancer screening tests than their counterparts in the control group. While our study revealed an increased occurrence of cancers in patients with GD, this finding might be partly attributed to the more rigorous surveillance procedures employed in this patient population.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Clin Med Year: 2023 Document type: Article Affiliation country: Israel Country of publication: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Clin Med Year: 2023 Document type: Article Affiliation country: Israel Country of publication: Switzerland